Scientists at the Wellcome Sanger Institute have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
Reported today (16 July 2018) in the journal Nature Biotechnology, the study also revealed that standard tests for detecting DNA changes miss finding this genetic damage, and that caution and specific testing will be required for any potential gene therapies.
CRISPR/Cas9 is one of the newest genome editing tools. It can alter sections of DNA in cells by cutting at specific points and introducing changes at that location. Already extensively used in scientific research, CRISPR/Cas9 has also been seen as a promising way to create potential genome editing treatments for diseases such as HIV, cancer or sickle cell disease. Such therapeutics could inactivate a disease-causing gene, or correct a genetic mutation. However, any potential treatments would have to prove that they were safe.
Previous research had not shown many unforeseen mutations from CRISPR/Cas9 in the DNA at the genome editing target site. To investigate this further the researchers carried out a full systematic study in both mouse and human cells and discovered that CRISPR/Cas9 frequently caused extensive mutations, but at a greater distance from the target site.
The researchers found many of the cells had large genetic rearrangements such as DNA deletions and insertions. These could lead to important genes being switched on or off, which could have major implications for CRISPR/Cas9 use in therapies. In addition, some of these changes were too far away from the target site to be seen with standard genotyping methods.
“This is the first systematic assessment of unexpected events resulting from CRISPR/Cas9 editing in therapeutically relevant cells, and we found that changes in the DNA have been seriously underestimated before now. It is important that anyone thinking of using this technology for gene therapy proceeds with caution, and looks very carefully to check for possible harmful effects.”
Professor Allan Bradley, corresponding author on the study from the Wellcome Sanger Institute
“My initial experiment used CRISPR/Cas9 as a tool to study gene activity, however it became clear that something unexpected was happening. Once we realised the extent of the genetic rearrangements we studied it systematically, looking at different genes and different therapeutically relevant cell lines, and showed that the CRISPR/Cas9 effects held true.”
Michael Kosicki, the first author from the Wellcome Sanger Institute
The work has implications for how CRISPR/Cas9 is used therapeutically and is likely to re-spark researchers’ interest in finding alternatives to the standard CRISPR/Cas9 method for gene editing.
“This study is the first to assess the repertoire of genomic damage arising at a CRISPR/Cas9 cleavage site. While it is not known if genomic sites in other cell lines will be affected in the same way, this study shows that further research and specific testing is needed before CRISPR/Cas9 is used clinically.”
Professor Maria Jasin, an independent researcher from Memorial Slone Kettering Cancer Centre, New York, who was not involved in the study
Learn more: Controversial study raises new doubts over unwanted genetic damage caused by CRISPR
The Latest on: CRISPR/Cas9
[google_news title=”” keyword=”CRISPR/Cas9″ num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: CRISPR/Cas9
- Barclays Maintains CRISPR Therapeutics (CRSP) Equal-Weight Recommendationon June 1, 2023 at 7:53 am
Fintel reports that on June 1, 2023, Barclays maintained coverage of CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 31.77% Upside As of May 11, ...
- ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreementon June 1, 2023 at 1:24 am
ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Applied Biological Materials Inc ('abm,'). This is a non-exclusive licensing agreement granting abm access to the ERS ...
- Chinese scientists develop new gene-editing tool that differs in approach to CRISPR-Cas9on May 31, 2023 at 7:51 am
Unlike the well-known gene-editing tool CRISPR-Cas9 – which acts as “molecular scissors” that can cut the two strands of DNA in the genome and relies on the cell’s self-healing mechanism to repair – ...
- CRISPR Therapeutics: A Galaxy's Worth of Deep Valueon May 31, 2023 at 4:45 am
CRISPR's nascent in vivo therapeutics program, though, is where things get truly interesting from a value creation standpoint. With a strategy focusing on gene disruption and whole gene correction, ...
- CRISPR Gene Editing Newson May 30, 2023 at 5:00 pm
May 25, 2023 — A new tool which could help reduce the spread of antimicrobial resistance is showing early promise, through exploiting a bacterial immune system as a gene editing ...
- William Blair Reiterates CRISPR Therapeutics (CRSP) Outperform Recommendationon May 30, 2023 at 12:07 pm
Fintel reports that on May 30, 2023, William Blair reiterated coverage of CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform recommendation. Analyst Price Forecast Suggests 30.51% Upside As of May 11 ...
- Researchers Find New Way to Improve Nonviral Gene Editingon May 30, 2023 at 9:00 am
Gene editing is a powerful method for both research and therapy. Since the advent of the Nobel Prize-winning CRISPR/Cas9 technology, a quick and accurate ...
- If I’d invested £1k in CRISPR Therapeutics shares on January 3, here’s what I’d have now!on May 26, 2023 at 8:45 pm
This could be the most exciting growth stock out there. Dr James Fox takes a closer look at CRISPR Therapeutics shares after the recent rally. The post If I’d invested £1k in CRISPR Therapeutics ...
- Worldwide experts come to CU Boulder to discuss CRISPR-Cas9 ethics, future of gene editingon May 24, 2023 at 1:36 am
Experts from around the world came to the University of Colorado Boulder on Tuesday to discuss the future, ethics and possibilities related to a technology called CRISPR-Cas9, a gene-cutting ...
via Bing News